Stalobacin: Discovery of Novel Lipopeptide Antibiotics with Potent Antibacterial Activity against Multidrug-Resistant Bacteria.

Aminoglycosides / pharmacology Anti-Bacterial Agents / chemistry Drug Evaluation, Preclinical Drug Resistance, Multiple, Bacterial / drug effects Gram-Negative Bacteria / drug effects Gram-Positive Bacteria / drug effects Lipoglycopeptides / pharmacology Lipopeptides / chemistry Microbial Sensitivity Tests

Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
11 06 2020
Historique:
pubmed: 8 5 2020
medline: 13 11 2020
entrez: 8 5 2020
Statut: ppublish

Résumé

A novel lipopeptide antibiotic, stalobacin I (

Identifiants

DOI: 10.1021/acs.jmedchem.0c00295 PMID: 32378891
pubmed: 32378891
doi: 10.1021/acs.jmedchem.0c00295
doi:

Substances chimiques

Aminoglycosides 0
Anti-Bacterial Agents 0
Lipoglycopeptides 0
Lipopeptides 0
telavancin XK134822Z0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6090-6095

Auteurs

Kouhei Matsui (K)

Pharmaceutical Research Center, Shionogi TechnoAdvance Research Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
Pharmaceutical Research Center, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.
ORCID: 0000-0002-9315-3203

Yukiko Kan (Y)

Pharmaceutical Research Center, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.

Junko Kikuchi (J)

Pharmaceutical Research Center, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.

Keisuke Matsushima (K)

Pharmaceutical Research Center, Shionogi TechnoAdvance Research Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.

Miki Takemura (M)

Pharmaceutical Research Center, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.

Hideki Maki (H)

Pharmaceutical Research Center, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.

Iori Kozono (I)

Pharmaceutical Research Center, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.

Taichi Ueda (T)

Pharmaceutical Research Center, Shionogi & Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.

Kazuyuki Minagawa (K)

Pharmaceutical Research Center, Shionogi TechnoAdvance Research Co., Ltd., 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Management of the infected total elbow arthroplasty.

Joaquin Sanchez-Sotelo
1.00
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Menthol as an effective inhibitor of quorum sensing and biofilm formation in Candida albicans and Candida glabrata by targeting the transcriptional repressor TUP1.

Pouria Khodavandi, Maryam Miri Soogh, Fahimeh Alizadeh et al.
1.00
Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol

Classifications MeSH

questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Stalobacin: Discovery of Novel Lipopeptide...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Stalobacin: Discovery of Novel Lipopeptide...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Stalobacin: Discovery of Novel Lipopeptide...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance bactérienne aux médicaments › Stalobacin: Discovery of Novel Lipopeptide...
questionsmedicales.fr › Bactéries › Bactéries à Gram négatif › Stalobacin: Discovery of Novel Lipopeptide...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Stalobacin: Discovery of Novel Lipopeptide...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Lipopeptides › Lipoglycopeptides › Stalobacin: Discovery of Novel Lipopeptide...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Lipopeptides › Stalobacin: Discovery of Novel Lipopeptide...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Stalobacin: Discovery of Novel Lipopeptide...